iOmx
Edit

iOmx

http://iomx.de/
Last activity: 06.10.2021
Active - Reference to iOmx Therapeutics AG
Categories: DevelopmentHuman
Artículos personalizados con papel y vinil.
Mentions
8
Employees: 11-50
Total raised: $120.2M
Founded date: 2016

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
05.10.2021Series B$75.36M-
04.11.2016Series A$44.84M-

Mentions in press and media 8

DateTitleDescription
06.10.2021iOmx raises 65 million eurosMartinsried-based iOmx Therapeutics AG has closed a 65 million euros Series B financing round. The financing was led by Athos Service GmbH - the family office of the Strüngmann family - and MIG Capital AG, with participation from existing i...
06.10.2021Germany's iOmx Therapeutics raises €65MAthos Service and MIG Capital have co-led a €65 million Series B for drug discovery startup iOmx Therapeutics, with participation from existing investors Wellington Partners, Sofinnova Partners and M Ventures. Munich-based iOmx develops can...
06.10.2021iOmx Therapeutics raises EUR 65 million in Series B roundiOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round totaling EUR 65 million.
05.10.2021PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B roundDGAP-News: iOmx Therapeutics AG / Key word(s): Financing iOmx Therapeutics raises EUR 65 million in Series B round 2021-10-05 / 10:30 The issuer is solely responsible for the content of this announcement. -----------------------------------...
05.10.2021IOmx Therapeutics : raises EUR 65 million in Series B roundDGAP-News: iOmx Therapeutics AG / Key word(s): Financing iOmx Therapeutics raises EUR 65 million in Series B round 05.10.2021 / 10:30 The issuer is solely responsible for the content of this announcement. iOmx Therapeutics raises EUR 65 mil...
04.11.2016iOmx Therapeutics Raises €40M in Series A FundingiOmx Therapeutics AG, a Martinsried, near Munich, Germany-based biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, recently closed a €40m Series A financing round. The round was co-led by MPM ...
22.09.2016Wellington invests in iOmx €40m Series AiOmx Therapeutics raises EUR 40 million in Series A round led by MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures
22.09.2016iOmx Therapeutics Raises EUR 40 Million in Series A round-

Reviews 0

Sign up to leave a review

Sign up Log In